Full Text View
Tabular View
No Study Results Posted
Related Studies
Phase II Trial of Combined Modality Treatment in Primary Central Nervous System Lymphoma
This study has been completed.
Study NCT00210314   Information provided by International Extranodal Lymphoma Study Group (IELSG)

First Received on September 13, 2005.   Last Updated on July 22, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Lymphoma, B Cell
Additional conditions recognized in this trial
Lymphoma
Lymphoma, B-Cell
More general conditions related to this trial
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoma, Non-Hodgkin
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Interventions listed in this trial
high dose methotrexate
high dose cytarabine
radiotherapy
Additional drug interventions recognized in this trial
Cytarabine
Methotrexate
More general drug interventions related to this trial
Abortifacient Agents
Abortifacient Agents, Nonsteroidal
Anti-Infective Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antirheumatic Agents
Antiviral Agents
Dermatologic Agents
Enzyme Inhibitors
Folic Acid Antagonists
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors
Pharmacologic Actions
Physiological Effects of Drugs
Reproductive Control Agents
Therapeutic Uses
Sponsors listed in this trial
International Extranodal Lymphoma Study Group (IELSG)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services